Methods for determining the prognosis for patients with a prostate neoplastic condition using inhibitor of apoptosis polypeptides
The invention provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient.
1. A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising:
(a) measuring the level of XIAP, wherein XIAP comprises SEQ ID NO:2, in a neoplastic prostate tissue sample from said patient, and
(b) comparing the level of XIAP in said sample to a reference level of XIAP in non-transformed prostate cells,
wherein an increased level of XIAP in said sample compared to the reference level indicates a prognosis of increased survival of said patient.
2. The method of claim 1 , wherein said survival is overall survival.
3. The method of claim 1 , wherein said survival is longer disease-free survival.
4. The method of claim 1 , wherein said measuring comprises using an antibody specifically reactive with the sequence encoded by SEQ ID NO:2 of said XIAP.
5. The method of claim 1 , wherein said patient has an early stage of prostate cancer.
6. The method of claim 1 , wherein said level of XIAP is used to determine the proper course of treatment for said patient.
7. The method of claim 1 , further comprising measuring the level of a second biomarker in said neoplastic prostate tissue sample and comparing the level of said second biomarker in said sample to a reference level of said second biomarker in non-transformed prostate cells, wherein the relative level of said second biomarker to said reference level indicates a prognosis for survival of said patient, wherein said second biomarker is an IAP biomarker selected from the group consisting of a cIAP2 polypeptide comprising SEQ ID NO:6, a cIAP1 polypeptide comprising SEQ ID NO:4, and Survivin.
8. The method of claim 7 , wherein said IAP biomarker is the cIAP1 polypeptide comprising SEQ ID NO:4.
9. The method of claim 7 , wherein said IAP biomarker is the cIAP2 polypeptide comprising SEQ ID NO:6.
10. The method of claim 7 , wherein said IAP biomarker is Survivin.
11. The method of claim 1 , further comprising measuring the level of a second biomarker in said neoplastic prostate tissue sample and comparing the level of said second biomarker in said sample to a reference level of said second biomarker in non-transformed prostate cells, wherein the relative level of said second biomarker to said reference level indicates a prognosis for survival of said patient, wherein said second biomarker is an IAP biomarker selected from the group consisting of a cIAP2 polypeptide comprising SEQ ID NO:6 and a cIAP1 polypeptide comprising SEQ ID NO:4.
12. The method of claim 11 , wherein said IAP biomarker is the cIAP2 polypeptide comprising SEQ ID NO:6.
13. The method of claim 11 , wherein said IAP biomarker is the cIAP1 polypeptide comprising SEQ ID NO:4.
14. A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising:
(a) measuring a level of XIAP, wherein XIAP comprises SEQ ID NO:2, in a neoplastic prostate tissue sample from said patient, and
(b) classifying said patient as belonging to either a first or second group of patients, wherein said first group of patients having a high level of XIAP relative to a reference level in non-transformed prostate cells is classified as having a prognosis for increased survival compared to said second group of patients having a low level of XIAP relative to said reference level.
15. The method of claim 14 , wherein said survival is overall survival.
16. The method of claim 14 , wherein said survival is longer disease-free survival.
17. The method of claim 14 , wherein said measuring comprises using an antibody specifically reactive with the sequence encoded by SEQ ID NO:2 of said XIAP.
18. The method of claim 14 , wherein said patient has an early stage of prostate cancer.